BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (Nasdaq: NRGN), a drug discovery and development company, today announced financial results for the first quarter ended March 31, 2007. Neurogen recognized a net loss for the first quarter of 2007 of $19.3 million, or $0.46 per share on 41.7 million weighted average shares outstanding. This compares to a net loss during the first quarter of 2006 of $14.3 million, or $0.42 per share on 34.5 million weighted average shares outstanding.
